Therapeutic antibody gene transfer: an active approach to passive immunity (Q34344211)

1 August 2017

1 reference

title

Therapeutic antibody gene transfer: an active approach to passive immunity (English)

1 reference

1 August 2017

1 reference

Joost M Bakker

1

1 reference

PubMed ID

15336642

1 August 2017

Wim K Bleeker

series ordinal

2

1 reference

PubMed ID

15336642

1 August 2017

Paul W H I Parren

series ordinal

3

1 reference

1 August 2017

1 September 2004

1 reference

1 August 2017

1 reference

1 August 2017

10

1 reference

1 August 2017

3

1 reference

1 August 2017

411-416

1 reference

Renaissance of cancer therapeutic antibodies

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Therapeutic antibodies: magic bullets hit the target.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Production of complex human glycoproteins in yeast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Gene therapy progress and prospects: adenoviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

High In Vivo Production of a Model Monoclonal Antibody on Adenoviral Gene Transfer

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

inferred from DOI database lookup

7 January 2021

based on heuristic

Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Gene therapy and the germ line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Gene therapy. Safer and virus-free?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Gene therapy. What to do when clear success comes with an unclear risk?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Immunotherapeutic gene transfer into muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Systemic immunological effects of cytokine genes injected into skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Plasmid DNA encoding transforming growth factor-beta1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Intramuscular administration of expression plasmids encoding interferon-gamma receptor/IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Prevention of experimental allergic encephalomyelitis by intramuscular gene transfer with cytokine-encoding plasmid vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Progress and prospects: naked DNA gene transfer and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Intravenous delivery of naked plasmid DNA for in vivo cytokine expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Efficient expression of naked dna delivered intraarterially to limb muscles of nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Physicochemical optimisation of plasmid delivery by cationic lipids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Gene therapy progress and prospects: nonviral vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Theory and in vivo application of electroporative gene delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

In vivo gene delivery by electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Gene transfer into muscle by electroporation in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

High-efficiency gene transfer into skeletal muscle mediated by electric pulses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Electropermeabilization of skeletal muscle enhances gene transfer in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Intramuscular gene transfer of soluble B7.1/IgG(1) fusion cDNA induces potent antitumor immunity as an adjuvant for DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Direct gene transfer into rat articular cartilage by in vivo electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

In vivo gene electroinjection and expression in rat liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Depth-targeted efficient gene delivery and expression in the skin by pulsed electric fields: an approach to gene therapy of skin aging and other diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Electroporation improves the efficacy of DNA vaccines in large animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

In vivo electroporation improves immune responses to DNA vaccination in sheep.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Accelerated immune response to DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Enhancer-dependent expression of human kappa immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Electric field-induced cell fusion and human monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Monoclonal antibodies produced by muscle after plasmid injection and electroporation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Clinical trials of antibody therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Mechanism of action of anti-HER2 monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Nuclear targeting of Bax during apoptosis in human colorectal cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Optimum dosage regimen of palivizumab?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Optimizing anti-TNF treatment in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Anti-cytokine therapeutics and infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.06.865

10.1016/J.YMTHE.2004.06.865

7 January 2021

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

15336642